We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Test Approved For Viruses Linked To Leukemia

By LabMedica International staff writers
Posted on 11 Apr 2012
A test has been approved that will detect antibodies to viruses in donors of human blood and blood components that are associated with several diseases.

The test can be used to both screen the blood supply for antibodies to Human T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type II (HTLV-II), and help diagnose infection with these viruses, which are associated with some forms of leukemia and neurologic diseases. More...


The HTLV-I/II Microelisa System is intended for screening living individual human donors, including volunteer donors of whole blood and blood components for the presence of HTLV antibodies. It is also approved for testing serum and plasma specimens to screen potential organ donors when specimens are obtained while the donor’s heart is still beating. It is not intended to be used to screen cord blood specimens or cadaveric blood specimens.

Developed as a standard two-step indirect microelisa system assay, the HTLV-I/II Microelisa System contains coated 96-well microwell plates, color-coded, liquid negative and positive control. Derived from purified and inactivated HTLV-I viral lysate, a purified HTLV-II viral lysate, and a recombinant HTLV-I p21E antigen, the HTLV-I/II Microelisa System is an enzyme-linked immunosorbent assay (ELISA). The HTLV-I/II Microelisa System is manufactured by Avioq Inc., (Research Triangle Park, NC, USA). This Avioq test has received approval from the US Food and Drug Administration (FDA; Silver Spring, MD, USA).

The Avioq HTLV-I/II assay features a user-friendly microplate design suitable for various testing volumes and automation. In addition to being used as a manual assay, the assay is also intended for use with the ORTHO Summit System (Ortho Clinical Diagnostics, Rochester, NY, USA) in the screening of blood donors. Both HTLV-I and HTLV-II can be transmitted through transfusion, reuse of syringes, and by breast-feeding from infected mothers.

Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said, "Since 2008, there has been only one FDA-licensed donor screening test available for detection of antibodies to HTLV. This approval provides an additional test for HTLV, providing greater flexibility to blood establishments and helping to assure the safety of the blood supply." Screening of all blood donors in the USA for evidence of HTLV infections is required to assure the safety of blood transfusions.

Related Links:

Avioq Inc.
Ortho Clinical Diagnostics
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.